Length: 00:16:49
Size: 7.70MB
Thought Leader: Barry Eisenstein, M.D., Senior VP, Scientific Affairs, Cubist Pharmaceuticals
Taren Grom, Cofounder and Editor of PharmaVOICE, and Dr. Eisenstein discuss the concept of a "translational connection" development model and how this shift in thinking can be employed to create new therapies to address unmet medical need in infectious disease in Part 1 of a 2-part series.
For more information on how you can be featured in a podcast, contact Dan Limbach at dlimbach@pharmavoice.com or call him at (847) 594-0157.
No comments:
Post a Comment